Three key lessons for digital health investors from the demise of Babylon Health
When Babylon Health listed in New York in 2021, the telehealth company was valued at $4.2bn. Within a year later the stock price collapsed and it later filed for bankruptcy. The company’s British assets sold for only £500k. We look at three key lessons for digital health investors.
Operators of acute hospitals, day-surgery and outpatient facilities including opthalmic, imaging centres, cancer and radiotherapy clinics, and ambulance services
Market opportunities for surgical ophthalmic equipment and products
Johan Ottosson, Senior Associate and Dr. Victor Chua, Senior Partner see significant opportunities in the market for surgical ophthalmic equipment and products
Johan Ottosson, Senior Associate and Dr. Victor Chua, Senior Partner see significant opportunities in the market for surgical ophthalmic equipment and products
Radiopharmaceuticals - where hot molecules meet cold capital
Radiopharmaceuticals remains a hot topic in 2026, with continued investment from both big and mid-sized pharma, and private equity in the last twelve months. Will Johnson, engagement manager, Lakshiv Dhingra, clinical fellow, and Victor Chua, Partner, at Mansfield Advisors outline key developments and potential asset classes for private equity investors considering the sector.
Johan Ottosson, Senior Associate and Dr. Victor Chua, Senior Partner see significant opportunities in the market for surgical ophthalmic equipment and products
Life science tools strategy from people who know the bench
We advise investors and firms across the tools, technologies and services that make modern science possible. Our team includes scientists who have worked at the bench. So we can judge the technology as well as the market.
The picks and shovels of modern science
Life sciences is a picks-and-shovels market. Whatever happens to any single drug, the industry keeps buying instruments, consumables, reagents and data. That makes the sector attractive to investors. It also makes it crowded.
The gap between a durable tools business and a fragile one sits in the science. How embedded is the product in customer workflows? How exposed is it to technology shifts? Does demand come from funded, recurring research or from fashion? We help clients tell the difference.
